What Boehringer sees in Genelabs

What Boehringer sees in Genelabs Genelabs Technologies Inc. (GNLB) also raised its stature as a hepatitis play when Boehringer Mannheim America Ltd. became its second non-exclusive licensee in efforts to develop products to diagnose and screen hepatitis X virus (HXV). Boehringer has paid GNLB $10 million for signing the dotted line.

The entire deal, including milestones, could be worth $14 million to GNLB, and that excludes undisclosed royalty payments on Boehringer's sales of HXV products. GNLB retains the right to develop and market HXV confirmatory tests worldwide...